Shree Ganesh Remedies Ltd
Shree Ganesh Remedies Ltd Q3 FY25 Results & Presentation Highlights: Revenue ₹27.05 Cr, PAT ₹5.43 Cr
Q3 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Shree Ganesh Remedies Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3FY25 Revenue from Operations: ₹27.05 Cr - Q3FY24 Revenue from Operations: ₹27.97 Cr - Year-on-Year (YoY) Revenue Change: -3% - Quarter-on-Quarter (QoQ) Revenue Change: -16% (from ₹32.33 Cr in Q2FY25) - 9 Months FY25 Revenue: ₹84.16 Cr vs. EBITDA for Q3FY25: ₹9.90 crore, up 21% YoY - Operating Margin (EBITDA %) for Q3FY25: 36.6%, up 725 basis points YoY - Profit After Tax (PAT) for Q3FY25: ₹5.43 crore, up 13% YoY - The presentation does not explicitly state a specific margin outlook, but management commentary highlights robust margins from CRAMS projects offsetting margin pressure on traditional products.
From Shree Ganesh Remedies Ltd's Q3 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3FY25 Revenue from Operations: ₹27.05 Cr
- Q3FY24 Revenue from Operations: ₹27.97 Cr
- Year-on-Year (YoY) Revenue Change: -3%
- Quarter-on-Quarter (QoQ) Revenue Change: -16% (from ₹32.33 Cr in Q2FY25)
- 9 Months FY25 Revenue: ₹84.16 Cr vs. ₹88.11 Cr in 9MFY24, a -4% YoY change
- Volume Outlook:
- Management commentary notes a decline in revenue due to intensified competition and price reductions in traditional products despite volume growth.
- No volumetric growth expected in current quarter due to maintenance shutdown of Block 3.
- Increased output from Block 8 is expected to offset the volume decline from Block 3.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Shree Ganesh Remedies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ankleshwar site expansion with recently acquired 20,100 sq m land; total land now 36,500 sq m; CAPEX ₹26 crores for adjacent unit acquisition.
- Block 8 added in FY24 at Ankleshwar; CAPEX ₹15 crores; ramp-up progressing as planned; optimal capacity expected by early next financial year.
- Block 3 undergoing maintenance and refurbishment shutdown in current quarter; no volumetric growth expected this quarter due to this.
- Block 7 construction started; designed phase completed; expected completion by end Q4FY26; commercial production to start Q1FY27.
- Ample land for 4 more blocks (Blocks 7, 9, 10, 11) planned over coming years.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Shree Ganesh Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Shree Ganesh Remedies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹33 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Shree Ganesh Remedies Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key investor presentation takeaways from Wockhardt Ltd's Q3 FY25 investor presen
- NGL Fine Chem Ltd (Q3 FY25)
Q3FY25 revenue from operations: ₹89.10 crores, a year-on-year (Y-o-Y) increase of 1.30% (Page 8). Key investor presentation takeaways from NGL Fine Chem Ltd's Q
- Themis Medicare Ltd (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q3 FY25 investor presentation — and how i
- Lincoln Pharmaceuticals Ltd (Q3 FY25)
EBITDA:** ₹32.2 crore, up 16% year-on-year. Key investor presentation takeaways from Lincoln Pharmaceuticals Ltd's Q3 FY25 investor presentation — and how it ra
Frequently Asked Questions
What were Shree Ganesh Remedies Ltd Q3 FY25 results?
Q3FY25 Revenue from Operations: ₹27.05 Cr - Q3FY24 Revenue from Operations: ₹27.97 Cr - Year-on-Year (YoY) Revenue Change: -3% - Quarter-on-Quarter (QoQ) Revenue Change: -16% (from ₹32.33 Cr in Q2FY25) - 9 Months FY25 Revenue: ₹84.16 Cr vs. EBITDA for Q3FY25: ₹9.90 crore, up 21% YoY - Operating Margin (EBITDA %) for Q3FY25: 36.6%, up 725 basis points YoY - Profit After Tax (PAT) for Q3FY25: ₹5.43 crore, up 13% YoY - The presentation does not explicitly state a specific margin outlook, but management commentary highlights robust margins from CRAMS projects offsetting margin pressure on traditional products.
What is Shree Ganesh Remedies Ltd share price analysis?
Shree Ganesh Remedies Ltd currently shows a neutral. The stock trades at a P/E of 58.0 with a market cap of ₹896 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shree Ganesh Remedies Ltd planning capital expenditure?
Ankleshwar site expansion with recently acquired 20,100 sq m land; total land now 36,500 sq m; CAPEX ₹26 crores for adjacent unit acquisition.
Keep Shree Ganesh Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.